December 30, 2020

Professor Phil Beales

Professor Phil Beales

CEO at Jaguar Gene Therapy

Over the past 25 years, Professor Beales has led groundbreaking discoveries in ciliopathy research and advancements in patient care, specifically for a debilitating ciliopathic disease, Bardet-Biedl Syndrome. Beales established the first diagnostic criteria for BBS, co-identified the first BBS gene, opened specialized clinics for BBS patients in the UK that are funded by the NHS and is now working on breakthrough gene therapy treatments for BBS patients.